Prospective study with circulating tumor cells as potential prognosis biomarker in metastatic colorectal cancer.

• DOI: 10.1200/jco.2020.38.4_suppl.203
• Publication Date: 2020-02-04T21:41:51Z
• Authors: Virgilio Souza E ...; Emne Ali Abdallah; Celso Abdon Lopes...; Milena Shizue Tariki; Vinicius Fernando...; Ludmilla T.D. Chinen
• Keywords: Circulating tumor cell; Primary tumor

203 Background: Colorectal cancer (CRC) is one of the most common worldwide. Around 30% present metastatic disease at diagnosis and 50%–60% patients develop metastasis. New prognostic markers are needed circulating tumor cells (CTCs) a promising tool. Methods: Prospective study conducted by blood collection from 75 (pts) with CRC (mCRC), twice, 2 months interval, together image exams for therapeutic response evaluation. CTCs were detected ISET identified immunocytochemistry. Results: The mean age was 57.3 years old (24-81). RAS mutations in primary found 38% (19/50) left colon topography 41.3% (31/75). Comparing baseline CTC level (CTC1) first follow-up (CTC 2), pts CTC2 – CTC1 > 5.5 per ml demonstrated poor progression-free survival (PFS) (3.2 months) when compared to ≤ (9.1 (p= 0.005). median overall (OS) 24.5 1 1.5 34.2 those (HR=1.89, 95% CI, 1.01 3.52; p= 0.041). Patients mutation (P= 0.001), right 0.014) expression Multidrug Resistance Protein 0.044) had worse OS. By multivariable analyses, 1.5/mL 0.025) an independent factor. Conclusions: This prospective confirmed that counts important marker monitoring mCRC correlates other established factors. Clinical trial information: NCT02979470.